CERN Investigators Publish Paper on 5-FU

— Categories: CERN Research Articles     Posted on August 6, 2015

A phase I study of the drug called 5-fluorouracil (5-FU) examined the pharmacokinetics, safety, and tolerable dosing for children and young adults with recurrent ependymoma.

In the phase I clinical data, bolus 5-FU is well tolerated.

To read the Neuro-Oncology Article, click here.

Stay Informed with the CERN Newsletter

The CERN Foundation is committed to informing you with the latest ependymoma news and research. Join our mailing list for monthly updates.